stocks logo

RANI

Rani Therapeutics Holdings Inc
$
0.551
+0.019(3.571%)1D
  • Overview
  • Forecast
  • Valuation
  • Earnings
Line
Line
|
Candle
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
0.5886
Open
0.540
VWAP
--
Vol
942.84K
Mkt Cap
37.23M
Low
0.540
Amount
--
EV/EBITDA(TTM)
--
Total Shares
26.30M
EV
38.73M
EV/OCF(TTM)
--
P/S(TTM)
--
Rani Therapeutics Holdings, Inc. is a clinical-stage biotherapeutics company focused on advancing technologies to enable the development of orally administered biologics and drugs. The Company has developed the RaniPill capsule, which is a proprietary and patented platform technology, intended to replace subcutaneous injection or intravenous infusion of biologics and drugs with oral dosing. The RaniPill capsule is designed to deliver a variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. It has two configurations of the platform: the RaniPill GO and the RaniPill HC. The RaniPill GO is designed to deliver up to a 3 mg dose of drug in microtablet form with high bioavailability. It is also developing a high-capacity version of the RaniPill capsule known as the RaniPill HC. Its product candidate pipeline includes obesity programs (RT-114 and RT-116), immunology programs (RT-105 and RT-111) and endocrinology programs (RT-102 and RT-110).
Show More
2 Analyst Rating
up Image
1170.65% Upside
Wall Street analysts forecast RANI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for RANI is 7.00 USD with a low forecast of 5.00 USD and a high forecast of 9.00  USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Buy
0 Hold
0 Sell
Moderate Buy
up Image
1170.65% Upside
Current: 0.551
sliders
Low
5.00
Averages
7.00
High
9.00
Oppenheimer
Oppenheimer
Outperform
to
NULL
downgrade
$14 -> $4
2025-05-16
Reason
Oppenheimer lowered the firm's price target on Rani Therapeutics to $4 from $14 and keeps an Outperform rating on the shares following quarterly and business update. The firm anticipates a mid-2025 initiation of the Phase 1 study for RT-114, an oral RaniPill containing 200microL of ProGen's GLP-1/GLP-2 receptor agonist, PG-102. In March, Rani presented preclinical data demonstrating comparable bioavailability between RT-114 and subcutaneous PG-102 supporting its potential as an effective oral obesity treatment. Oppenheimer views Rani's expansion into obesity as a value-driver, differentiated by tolerability and flexible dosing. Given the company's financial position and advancing RT-114/obesity becoming its prime focus, the firm removes RT-111/psoriasis from its valuation.
HC Wainwright & Co.
Mitchell Kapoor
Strong Buy
Reiterates
$9
2025-04-03
Reason
Canaccord Genuity
Edward Nash
Strong Buy
Maintains
$9
2025-02-26
Reason
HC Wainwright & Co.
Raghuram Selvaraju
Strong Buy
Reiterates
$9
2025-02-07
Reason
HC Wainwright & Co.
Mitchell Kapoor
Strong Buy
Reiterates
$9
2024-11-19
Reason
HC Wainwright & Co.
Mitchell Kapoor
Strong Buy
Reiterates
$9
2024-10-18
Reason

Valuation Metrics

The current forward P/E ratio for Rani Therapeutics Holdings Inc (RANI.O) is -0.99, compared to its 5-year average forward P/E of -5.82. For a more detailed relative valuation and DCF analysis to assess Rani Therapeutics Holdings Inc 's fair value, click here.

Forward PE

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-5.82
Current PE
-0.99
Overvalued PE
-0.24
Undervalued PE
-11.41

Forward EV/EBITDA

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-2.31
Current EV/EBITDA
-0.57
Overvalued EV/EBITDA
-0.16
Undervalued EV/EBITDA
-4.47

Forward PS

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
441.31
Current PS
0.00
Overvalued PS
1269.75
Undervalued PS
-387.12

Financials

Annual
Quarterly
FY2025Q1
172.00K
Total Revenue
FY2025Q1
YoY :
-14.40%
-12.01M
Operating Profit
FY2025Q1
YoY :
-13.81%
-12.74M
Net Income after Tax
FY2025Q1
YoY :
-24.14%
-0.22
EPS - Diluted
FY2025Q1
YoY :
-12.95%
-8.20M
Free Cash Flow
FY2025Q1
100.00
Gross Profit Margin - %
FY2025Q1
N/A
FCF Margin - %
FY2025Q1
-7.41K
Net Margin - %

Trading Trends

Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
10.1M
USD
1
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
2
50.0K
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months

RANI News & Events

Events Timeline

2025-07-15 (ET)
2025-07-15
09:02:51
Rani Therapeutics prices 4.35M shares at 40c in registered direct offering
select
2025-07-07 (ET)
2025-07-07
07:05:31
Genelux appoints Eric Groen as general counsel, corporate secretary, CCO
select
2025-05-19 (ET)
2025-05-19
08:07:47
Rani Therapeutics announces research agreement with Chugai
select
Sign Up For More Events

News

4.5
07-15Benzinga
Nasdaq Gains Over 100 Points; Wells Fargo Earnings Top Views
9.5
07-15Benzinga
Dow Falls Over 100 Points; JPMorgan Posts Upbeat Earnings
7.5
07-14Benzinga
Why Datavault AI Shares Are Trading Higher By 7%; Here Are 20 Stocks Moving Premarket
Sign Up For More News

FAQ

arrow icon

What is Rani Therapeutics Holdings Inc (RANI) stock price today?

The current price of RANI is 0.5509 USD — it has increased 3.57 % in the last trading day.

arrow icon

What is Rani Therapeutics Holdings Inc (RANI)'s business?

arrow icon

What is the price predicton of RANI Stock?

arrow icon

What is Rani Therapeutics Holdings Inc (RANI)'s revenue for the last quarter?

arrow icon

What is Rani Therapeutics Holdings Inc (RANI)'s earnings per share (EPS) for the last quarter?

arrow icon

What changes have occurred in the market's expectations for Rani Therapeutics Holdings Inc (RANI)'s fundamentals?

arrow icon

How many employees does Rani Therapeutics Holdings Inc (RANI). have?

arrow icon

What is Rani Therapeutics Holdings Inc (RANI) market cap?